Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab and Chemoradiotherapy in LACC
NCT06916117Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Cervical Cancer (CC), sponsored by Renji Hospital. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06916117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916117.